Technology
Immagina Biotechnology s.r.l. proudly holds the exclusive research use license for the groundbreaking nano-tRNAseq technology, originally developed by the Novoa Lab at the Centre for Genomic Regulation in Barcelona, Spain and introduced in Nature Biotechnology in 20231.
nano-tRNAseq marks a significant milestone in tRNA and translatomics research by enabling comprehensive sequencing of tRNA molecules in their full-length, native state, allowing for quantification of tRNA abundance and detection of tRNA modifications. nano-tRNAseq technology empowers researchers to easily pinpoint tRNA isoforms and post-translational modifications, offering deeper understanding of the intricate workings of these fundamental cellular components.
1. Lucas M, et al. (2023) Nature Biotechnology. 42(1):1-15. doi 10.1038/s41587-023-01743-6.
Information
Immagina has improved the published methods for this technology to offer a unique and comprehensive product/service that includes multiplexing, comprehensive quality control, and extensive bioinformatics reporting. Contact us for early access to the nano-tRNAseq platform and ask about special introductory rates.
Applications
- Expand translatome studies
- Quantify tRNA abundance;
- Identify tRNA modifications
- Explore ribosome-embedded tRNA Perform codon-anticodon analysis
- Maximize drug discovery efforts
- Investigate tRNA distribution in tissues and fluids
